Anika Therapeutics (ANIK) Cash from Financing Activities (2010 - 2026)

Anika Therapeutics (ANIK) has 17 years of Cash from Financing Activities data on file, last reported at -$10.3 million in Q1 2026.

• On a quarterly basis, Cash from Financing Activities fell 90.27% year-over-year to -$10.3 million in Q1 2026; TTM through Mar 2026 was -$15.5 million, a 2.73% increase from a year earlier, with the FY2025 full-year figure at -$10.6 million, up 17.11% from the prior year.
• Cash from Financing Activities for Q1 2026 stood at -$10.3 million, down from -$5.3 million in the prior quarter.
• Over the last five years, Cash from Financing Activities for ANIK reached as high as $667000.0 in Q4 2022 and fell as low as -$10.3 million in Q1 2026.
• Historically, Cash from Financing Activities has averaged -$2.6 million across 5 years, with a median of -$1.6 million in 2023.
• Across the five-year window, Cash from Financing Activities jumped 1011.67% in 2022 and slumped 10645.65% in 2023, its largest moves.
• Year by year, Cash from Financing Activities stood at $667000.0 in 2022, then slumped by 48.73% to $342000.0 in 2023, then slumped by 1665.5% to -$5.4 million in 2024, then increased by 1.4% to -$5.3 million in 2025, then sank by 96.0% to -$10.3 million in 2026.
• Per Business Quant data, the three most recent Cash from Financing Activities figures were -$10.3 million in Q1 2026, -$5.3 million in Q4 2025, and -$13000.0 in Q3 2025.